Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 196

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

High Oct4 expression: implications in the pathogenesis of neuroblastic tumours

Open access
Monferrer, Ezequiel, Burgos-Panadero, Rebeca, Blanquer-Maceiras, Maite, Cañete, Adela, Navarro, Samuel, Noguera, Rosa · 2019 · BMC Cancer

Abstract

BACKGROUND: Neuroblastic tumours (NBTs) are paediatric solid tumours derived from embryonic neural crest cells which harbour their own cancer stem cells (CSC). There is evidence indicating that CSC may be responsible for tumour progression, chemotherapy resistance and recurrence in NBTs. Oct4 is a transcription factor which plays a key role in mammal embryonic development and stem cell fate regulation. The aim of the study is to elucidate the clinical significance of Oct4 in NBTs. METHODS: cell percentage. Survival analysis was carried out with Kaplan-Meier curves and log-rank test. Additionally, a multivariate Cox regression analysis with the stepwise backwards (Wald) method was undertaken to calculate the impact of Oct4 expression level on survival. RESULTS: We found that tumours with a high proportion of cells expressing Oct4 correlated statistically with undifferentiated and poorly differentiated neuroblastoma / nodular ganglioneuroblastoma, and that Oct4 expression was not present in ganglioneuroma (p < 0.05). Statistical analysis also indicated a relationship between high Oct4 expression levels, high-risk patients according to the International Neuroblastoma Risk Group pre-treatment classification parameters, larger blood vessels and low survival rates. CONCLUSIONS: These results suggest that the Oct4 gene may regulate NBT pathogenic differentiation pathways, and should thus be considered as a target for knockdown when developing novel therapies for high-risk NBT patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12885-018-5219-3

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 49

  1. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369:2106–20. · DOI · Paper page
  2. Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev. 2010;36(4):277–85. · DOI · Paper page
  3. Vandesompele J, Van Roy N, Van Gele M, et al. Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromosomes Cancer. 1998;23(2):141–52. · doi:10.1002/(sici)1098-2264(199810)23:2<141::aid-gcc7>3.0.co;2-2
  4. Ambros IM, Speleman F, Ambros PF. Nervous system: peripheral neuroblastic tumours (neuroblastoma, ganglioneuroblastoma, ganglioneuroma). Atlas Genet Cytogenet Oncol Haematol. 2009;13(1):84–9.
  5. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer. 2003;3(3):203–16. · DOI · Paper page
  6. Ambros PF, Ambros IM, Brodeur GM, et al. International consensus for neuroblastoma molecular diagnostics: report from the international neuroblastoma risk group (INRG) biology committee. Br J Cancer. 2009;100(9):1471–82. · DOI · Paper page
  7. Cohn SL, Pearson AD, London WB, et al. The international neuroblastoma risk group (INRG) classification system: an INRG task force report. J Clin Oncol. 2009;27(2):289–97. · DOI · Paper page
  8. Pui CH, Gajjar AJ, Kane JR, Qaddoumi IA, Pappo AS. Challenging issues in paediatric oncology. Nat Rev Clin Oncol. 2011;8(9):540–9. · DOI · Paper page
  9. Kim RJ, Nam JS. OCT4 expression enhances features of cancer stem cells in a mouse model of breast cancer. Lab Anim Res. 2011;27(2):147–52. · DOI
  10. Kumar SM, Liu S, Lu H, et al. Acquired cancer stem cell phenotypes through Oct4-mediated dedifferentiation. Oncogene. 2012;31(47):4898–911. · DOI · Paper page
  11. Monk M, Holding C. Human embryonic genes re-expressed in cancer cells. Oncogene. 2001;20(56):8085–91. · DOI · Paper page
  12. Nichols J, Zevnik B, Anastassiadis K, et al. Formation of pluripotent stem cells in the mammalian embryo depends on the POU transcription factor Oct4. Cell. 1998;95(3):379–91. · DOI · Paper page
  13. Pan GJ, Chang ZY, Schöler HR, Duanqing PEI. Stem cell pluripotency and transcription factor Oct4. Cell Res. 2002;12(5–6):321–9. · DOI · Paper page
  14. Simandi Z, Horvath A, Wright LC, et al. OCT4 acts as an integrator of pluripotency and signal-induced differentiation. Mol Cell. 2016;63(4):647–61. · DOI
  15. Renshaw AA, Gould EW. OCT4 staining increases the detection of lymphatic/vascular invasion in pure seminoma of the testis obscured by prominent lymphohistiocytic inflammation. Pathology. 2016;48(3):210–3. · doi:10.1016/j.pathol.2016.02.009
  16. Emerson RE, Cheng L. Premalignancy of the testis and paratestis. Pathology. 2013;45(3):264–72. · doi:10.1097/pat.0b013e32835f3e1a
  17. Atlasi Y, Mowla SJ, Ziaee SA, Bahrami AR. OCT-4, an embryonic stem cell marker, is highly expressed in bladder cancer. Int J Cancer. 2007;120(7):1598–602. · doi:10.1002/ijc.22508
  18. Chen Z, Xu WR, Qian H, et al. Oct4, a novel marker for human gastric cancer. J Surg Oncology. 2009;99(7):414–9. · DOI
  19. Cheng L, Thomas A, Roth LM, Zheng W, Michael H, Karim FWA. OCT4: a novel biomarker for dysgerminoma of the ovary. Am J Surg Pathol. 2004;28(10):1341–6. · DOI
  20. Liu T, Sun B, Zhao X, et al. OCT4 expression and vasculogenic mimicry formation positively correlate with poor prognosis in human breast cancer. Int J Mol Sci. 2014;15(11):19634–49. · doi:10.3390/ijms151119634
  21. Villodre ES, Kipper FC, Pereira MB, Lenz G. Roles of OCT4 in tumorigenesis, cancer therapy resistance and prognosis. Cancer Treat Rev. 2016;51:1–9. · DOI
  22. Rodini CO, Suzuki DE, Saba-Silva N, et al. Expression analysis of stem cell-related genes reveal OCT4 as a predictor of poor clinical outcome in medulloblastoma. J Neuro-Oncol. 2012;106(1):71–9. · DOI
  23. Yang L, Zheng J, Xu T, Xiao X. Downregulation of OCT4 promotes differentiation and inhibits growth of BE (2)-C human neuroblastoma I-type cells. Oncol Rep. 2013;29(6):2191–6. · DOI
  24. Melone MA, Giulano M, Squillaro T, et al. Genes involved in regulation of stem cell properties: studies on their expression in a small cohort of neuroblastoma patients. Cancer Biol Ther. 2009;8(13):1300–6. · DOI
  25. Newton TC, Wolcott K, Roberts SS. Comparison of the side populations in pre-treatment and postrelapse neuroblastoma cell lines. Transl Oncol. 2010;3(4):246–51. · DOI
  26. Pezzolo A, Parodi F, Marimpietri D, et al. Oct-4+/tenascin C+ neuroblastoma cells serve as progenitors of tumour-derived endothelial cells. Cell Res. 2011;21(10):1470–86. · DOI
  27. Monajemzadeh M, Soleimani V, Vasei M, Koochakzadeh L, Karbakhsh M. Expression and prognostic significance of Oct4 and Nanog in neuroblastoma. APMIS. 2014;122(9):734–41. · doi:10.1111/apm.12207
  28. Yang S, Zheng J, Ma Y, et al. Oct4 and Sox2 are overexpressed in human neuroblastoma and inhibited by chemotherapy. Oncol Rep. 2012;28(1):186–92.
  29. Kaneko Y, Suenaga Y, Islam SM, et al. Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas. Cancer Sci. 2015;106(7):840–7. · DOI
  30. Hamilton PW, Bankhead P, Wang Y, et al. Digital pathology and image analysis in tissue biomarker research. Methods. 2014;70(1):59–73. · DOI · Paper page
  31. Laurinavicius A, Laurinaviciene A, Dasevicius D, et al. Digital image analysis in pathology: benefits and obligation. Anal Cell Pathol (Amst). 2012;35(2):75–8. · doi:10.1155/2012/243416
  32. Rizzardi AE, Johnson AT, Vogel RI, et al. Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagn Pathol. 2012;7(1):42. · DOI · Paper page
  33. Tadeo I, Berbegall AP, Castel V, et al. Extracellular matrix composition defines an ultra-high-risk group of neuroblastoma within the high-risk patient cohort. Br J Cancer. 2016;115(4):480–9. · DOI
  34. Soheili S, Asadi M, Farsinejad A. Distinctive expression pattern of OCT4 variants in different types of breast cancer. Cancer Biomarkers. 2017;18(1):69–76. · doi:10.3233/cbm-160675
  35. Hanahan D, Weinberg R. Hallmarks of Cancer. Cell. 2000;100:57–70. · DOI · Paper page
  36. Mierke CT. Physical break-down of the classical view on cancer cell invasion and metastasis. Eur J Cell Biol. 2013;92(3):89–104. · DOI
  37. Li GN, Livi LL, Gourd CM, Deweerd ES, Hoffman-Kim D. Genomic and morphological changes of neuroblastoma cells in response to three-dimensional matrices. Tissue Eng. 2007;13(5):1035–47. · DOI
  38. Tadeo I, Piqueras M, Montaner D, et al. Quantitative modeling of clinical, cellular, and extracellular matrix variables suggest prognostic indicators in cancer: a model in neuroblastoma. Pediatr Res. 2014;75(2):302–14. · DOI
  39. Tadeo I, Berbegall AP, Navarro S, Castel V, Noguera R. A stiff extracellular matrix is associated with malignancy in peripheral neuroblastic tumours. Pediatr Blood Cancer. 2017;64(9). https://doi.org/10.1002/pbc.26449 . · DOI
  40. Tadeo I, Berbegall AP, Escudero LM, Álvaro T, Noguera R. Biotensegrity of the extracellular matrix: physiology, dynamic mechanical balance, and implications in oncology and mechanotherapy. Front Oncol. 2014;4:39. · DOI
  41. Tadeo I, Bueno G, Berbegall AP, et al. Vascular patterns provide therapeutic targets in aggressive neuroblastic tumours. Oncotarget. 2016;7(15):19935–47. · DOI
  42. Samardzija C, Greening DW, Escalona R, et al. Knockdown of stem cell regulator Oct4A in ovarian cancer reveals cellular reprogramming associated with key regulators of cytoskeleton-extracellular matrix remodelling. Sci Rep. 2017;7:46312. · DOI
  43. Shimada H, Ambros IM, Dehner LP, et al. The international neuroblastoma pathology classification (the Shimada system). Cancer. 1999;86(2):364–72. · DOI · Paper page
  44. Yin X, Zhang BH, Zheng SS, et al. Coexpression of gene Oct4 and Nanog initiates stem cell characteristics in hepatocellular carcinoma and promotes epithelial-mesenchymal transition through activation of Stat3/snail signaling. J Hematol Oncol. 2015;8(1):23. · DOI · Paper page
  45. Chang CC, Shieh GS, Wu P, Lin CC, Shiau AL, Wu CL. Oct-3/4 expression reflects tumour progression and regulates motility of bladder cancer cells. Cancer Res. 2008;68(15):6281–91. · doi:10.1158/0008-5472.can-08-0094
  46. Dai X, Ge J, Wang X, Qian X, Zhang C, Li X. OCT4 regulates epithelial-mesenchymal transition and its knockdown inhibits colorectal cancer cell migration and invasion. Oncology Rep. 2013;29(1):155–60. · DOI
  47. Lin J, Zhang L, Huang H, et al. MiR-26b/KPNA2 axis inhibits epithelial ovarian carcinoma proliferation and metastasis through downregulating OCT4. Oncotarget. 2015;6(27):23793. · DOI
  48. Lin H, Sun LH, Han W, et al. Knockdown of OCT4 suppresses the growth and invasion of pancreatic cancer cells through inhibition of the AKT pathway. Mol Med Reps. 2014;10(3):1335–42. · doi:10.3892/mmr.2014.2367
  49. Liu X, Ma M, Duan X, Zhang H, Yang M. Knockdown of OCT4 may sensitize NSCLC cells to cisplatin. Clin Transl Oncol. 2017;19(5):587–92. · doi:10.1007/s12094-016-1569-y

Cited by

See all 196

Metadata

Authors
Monferrer, E., Burgos-Panadero, R., Blanquer-Maceiras, M., Cañete, A., Navarro, S., & Noguera, R.
Venue
BMC Cancer
Published
2019-01-03
Volume
19
Issue
1
Pages
1-1
ISSN
1471-2407 (ISSN-L)
OpenAlex
W2947601703
Cited by
196
References
2
FWCI
13.29
Type
journal article
Language
en
Open access
gold
Licence
creativecommons.org/licenses/by/4.0/ (tdm)
Funders
  • European Regional Development Fund (PI14/01008, PI17/01558)
  • CIBERONC (CB16/12/00484)
  • Fundación Científica Asociación Española Contra el Cáncer (FAECC2015/2016)
  • NEN Association
  • Neuroblastoma Foundation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: High Oct4 expression: implications in the pathogenesis of neuroblastic tumours. https://app.cochat.ai/papers/10.1186/s12885-018-5219-3
The paper
Monferrer, E., Burgos-Panadero, R., Blanquer-Maceiras, M., Cañete, A., Navarro, S., & Noguera, R. (2019). High Oct4 expression: implications in the pathogenesis of neuroblastic tumours. BMC Cancer. https://doi.org/10.1186/s12885-018-5219-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.